Evaluation of HIV-1 kinetic models using quantitative discrimination analysis

MOTIVATION Since the identification of human immunodeficiency virus (HIV) over twenty years ago, many mathematical models of HIV dynamics have been proposed. The purpose of this study was to evaluate intracellular and intercellular scale HIV models that best described the dynamics of viral and cell titers of a person, where parameters were determined using typically available patient data. In this case, 'best' was defined as the model most capable of describing experimental patient data and was determined by Bayesian-based model discrimination analysis and the ability to provide realistic results. RESULTS Twenty models of HIV-1 viral dynamics were initially evaluated to determine whether parameters could be obtained from readily available clinical data from established HIV-1 patients with stable disease. Based on this analysis, three models were chosen for further examination and comparison. Parameters were estimated using experimental data from a cohort of 338 people monitored for up to 2484 days. The models were evaluated using a Bayesian technique to determine which model was most probable. The model ultimately selected as most probable was overwhelmingly favored relative to the remaining two models, and it accounted for uninfected cells, infected cells and cytotoxic T lymphocyte dynamics. The authors developed a fourth model for comparison purposes by combining the features of the original three models. Parameters were estimated for the new model and the statistical analysis was repeated for all four models. The model that was initially favored was selected again upon model discrimination analysis. CONTACT srivasta@engr.uconn.edu.

[1]  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1990, Disease markers.

[2]  S Bonhoeffer,et al.  A stochastic model for primary HIV infection: optimal timing of therapy. , 1999, AIDS.

[3]  A S Perelson,et al.  Modeling HIV infection of CD4+ T-cell subpopulations. , 1994, Journal of theoretical biology.

[4]  Sonya J Snedecor,et al.  Comparison of three kinetic models of HIV-1 infection: implications for optimization of treatment. , 2003, Journal of theoretical biology.

[5]  M. Re,et al.  Quantification of human immunodeficiency virus type 1-infected mononuclear cells in peripheral blood of seropositive subjects by newly developed flow cytometry analysis of the product of an in situ PCR assay , 1994, Journal of clinical microbiology.

[6]  M A Nowak,et al.  Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. , 1997, Journal of theoretical biology.

[7]  Andrew N. Phillips,et al.  Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response , 1996, Science.

[8]  R. Gallo,et al.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Zack,et al.  CD4 on CD8(+) T cells directly enhances effector function and is a target for HIV infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  George E. P. Box,et al.  Model Discrimination and Criticism with Single-Response Data , 1996 .

[11]  S. J. Flint,et al.  Principles of Virology: Molecular Biology, Pathogenesis, and Control , 1999 .

[12]  G L Drusano,et al.  A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. , 1992, The New England journal of medicine.

[13]  A. Perelson Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[14]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[15]  B. Gazzard,et al.  Where does HIV live? , 2004, The New England journal of medicine.

[16]  Z. Grossman,et al.  Mathematical models of HIV pathogenesis , 1997, Nature Medicine.

[17]  M. Baseler,et al.  Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. , 1990, Annals of internal medicine.

[18]  W. E. Stewart,et al.  Discrimination and goodness of fit of multiresponse mechanistic models , 1998 .

[19]  P. Kahn Susceptibility Genes: Pointing a Way to Prevention? , 1996, Science.

[20]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R J D B,et al.  Target Cell Limited and Immune Control Models of HIV Infection : A Comparison , 1998 .

[22]  A S Perelson,et al.  Effect of Drug Efficacy and the Eclipse Phase of the Viral Life Cycle on Estimates of HIV Viral Dynamic Parameters , 2001, Journal of acquired immune deficiency syndromes.

[23]  A S Perelson,et al.  Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.

[24]  B. Walker,et al.  A rapid method for quantitating the frequency of peripheral blood cells containing HIV-1 DNA. , 1991, Journal of acquired immune deficiency syndromes.

[25]  H C Tuckwell,et al.  A stochastic model for early HIV-1 population dynamics. , 1998, Journal of theoretical biology.

[26]  S. Bloor,et al.  Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV‐1‐infected individuals , 1993, AIDS.

[27]  Steve Kaye,et al.  Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance , 2001, Journal of acquired immune deficiency syndromes.

[28]  S E Macatonia,et al.  Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. , 1990, Immunology.

[29]  Warren E. Stewart,et al.  Parameter estimation from multiresponse data , 1992 .

[30]  C H Fox,et al.  The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. , 1989, Science.

[31]  K. Nusbaum Book Review: Principles of Virology: Molecular Biology, Pathogenesis, and Control of Animal Viruses , 2004 .

[32]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[33]  J. Yin,et al.  Quantitative intracellular kinetics of HIV type 1. , 1999, AIDS research and human retroviruses.

[34]  M A Nowak,et al.  Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Huldrych F. Günthard,et al.  Quantification of In Vivo Replicative Capacity of HIV‐1 in Different Compartments of Infected Cells , 2001, Journal of acquired immune deficiency syndromes.

[36]  Martin A Nowak,et al.  Mathematical models of HIV pathogenesis and treatment. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[37]  W. Tan,et al.  Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. , 1998, Mathematical biosciences.

[38]  Anthony S Fauci,et al.  HIV and AIDS: 20 years of science , 2003, Nature Medicine.

[39]  M A Nowak,et al.  Human immunodeficiency virus drug therapy and virus load , 1997, Journal of virology.

[40]  Warren E. Stewart,et al.  Bayesian Estimation of Common Parameters From Multiresponse Data With Missing Observations , 1981 .

[41]  R. Pomerantz,et al.  High percentages of CD4‐positive lymphocytes harbor the HIV‐1 provirus in the blood of certain infected individuals , 1993, AIDS.

[42]  J. Albert,et al.  Few infected CD4+ T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection , 1991, Journal of virology.

[43]  R. Pomerantz,et al.  Twenty years of therapy for HIV-1 infection , 2003, Nature Medicine.

[44]  Sebastian Bonhoeffer,et al.  Glancing behind virus load variation in HIV-1 infection. , 2003, Trends in microbiology.

[45]  O. Bagasra,et al.  Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. , 1992, The New England journal of medicine.

[46]  S. Spector,et al.  Human immunodeficiency virus DNA is present in a high percentage of CD4+ lymphocytes of seropositive individuals. , 1991, The Journal of infectious diseases.

[47]  A S Perelson,et al.  Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. , 1998, Journal of theoretical biology.

[48]  P. Simmonds,et al.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers , 1990, Journal of virology.

[49]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[50]  Mario Roederer,et al.  T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.

[51]  M. Stevenson HIV-1 pathogenesis , 2003, Nature Medicine.